Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study

Maximilian J. Hochmair*, Alessandro Morabito, Desiree Hao, Cheng Ta Yang, Ross A. Soo, James C.H. Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten, Tanja Cufer

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

88 Scopus citations

Abstract

Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. Trial registration number: NCT0337077.

Original languageEnglish
Pages (from-to)2861-2874
Number of pages14
JournalFuture Oncology
Volume14
Issue number27
DOIs
StatePublished - 11 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2015 2018 Maximilian Hochmair.

Keywords

  • NSCLC
  • T790M
  • afatinib
  • osimertinib
  • sequential

Fingerprint

Dive into the research topics of 'Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study'. Together they form a unique fingerprint.

Cite this